Participating Faculty: The Evidence for Semaglutide 2.4 mg in Obesity From a Managed Care Perspective
Increasing Clinical Awareness of Obesity as a Serious, Chronic, Relapsing, and Treatable Disease
Patient Well-being and the Clinical and Economic Burdens Associated With Obesity in the United States
A Review of Current Guidelines for the Treatment of Obesity
Semaglutide 2.4-mg Injection as a Novel Approach for Chronic Weight Management
Managed Care Considerations of Weight Management Interventions for Obesity